#United States #Palo Alto #Surf Bio #SnapShot #Bryan Mazlish

Overview of the Event

Surf Bio, a pioneering biopharmaceutical company known for its innovative approach to delivering antibodies and biologics, has announced its participation in the 5th Annual Needham Private Biotech and MedTech Company Virtual 1×1 Forum, scheduled for October 14-15, 2025. CEO Bryan Mazlish will represent Surf Bio, engaging in one-on-one meetings that provide insights into the company's strategic approach and technological advancements.

Focus on SnapShot™ Technology

A highlight of the event will be Surf Bio's discussion on its proprietary SnapShot™ technology, which facilitates the subcutaneous administration of high-concentration formulations of monoclonal antibodies (mAbs) and other biologics. This technology aims to solve several challenges inherent in traditional infusion methods. By enhancing accessibility and manufacturing efficacy, SnapShot™ is set to revolutionize how patients receive biologic therapies. As drug pipelines continue to expand, innovative delivery platforms like SnapShot™ could significantly alleviate the pressures on healthcare systems and infusion centers.

Importance of Participation

Participation in the Needham Forum offers Surf Bio valuable exposure to investors and industry stakeholders. Through focused discussions, Bryan Mazlish will detail how SnapShot™ technology addresses key industry challenges, providing investors with a comprehensive understanding of Surf Bio's business model and development strategy. The company’s forward-looking approach aligns well with current trends toward more efficient healthcare delivery, focusing on patient accessibility and simplified manufacturing processes.

Event Details

For those interested in attending or learning more about the event, registration is available at Needham’s official website. The forum promises to be a significant platform for Biotech and MedTech discussions, bringing together innovators and investors from across the industry.

About Surf Bio

Established in Palo Alto, California, Surf Bio is redefining the landscape of biologic therapy by employing its unique SnapShot™ technology, designed for the development of ultra-high concentration formulations that can be administered easily. Preliminary safety and efficacy studies have shown that SnapShot™ allows for the creation of potent subcutaneous formulations of mAbs, enabling healthcare providers to deliver these therapies in more practical ways.

For more information about Surf Bio and its innovative approaches, visit the company’s website at www.surf.bio. The company’s commitment to improving biologic delivery could lead to significant advancements in patient care and ultimately better health outcomes.

Conclusion

The upcoming Needham Forum represents a critical opportunity for Surf Bio to showcase its cutting-edge SnapShot™ technology and expand its reach within the biopharmaceutical community. With rising demands for effective biologic therapies, innovations like SnapShot™ are essential for meeting the needs of both patients and healthcare systems. The insights shared by Bryan Mazlish at the forum will provide a closer look at the future of biologic delivery and Surf Bio’s role in shaping that future.